Mr. David Levine reports

DRI HEALTHCARE TRUST ANNOUNCES UPSIZED US$631.6 MILLION CREDIT FACILITIES

DRI Healthcare Trust has entered into an amendment agreement to the existing amended and restated credit agreement with a syndicate of banks providing up to $631.6-million (U.S.) of debt capacity. As part of the amendment, the interest rate on drawings was reduced by 0.25 per cent based on the trust's leverage ratio. The facilities are secured by all of the assets of the trust and most of its subsidiaries and the maturity date has been extended to Nov. 1, 2027, three years from the date of closing.

"We are fortunate for the ongoing strong support from our syndicate of top-tier lenders," said Amit Kapur, chief financial officer of the trust. "We have a solid and diversified capital structure, and this enhanced funding will help us continue executing our investment strategy. We have deployed over $185-million (U.S.) this year and still have nearly $300-million (U.S.) undrawn on the facilities. With a robust pipeline of opportunities ahead of us, we are confident we can achieve, and hopefully exceed, our $1.25-billion (U.S.) deployment target by the end of 2025 solely with the funding currently available to us."

The lending syndicate comprises Canadian Imperial Bank of Commerce and Royal Bank of Canada as co-lead arrangers and joint bookrunners and includes Bank of America N.A., JP Morgan Chase Bank N.A., National Bank of Canada, The Bank of Nova Scotia and The Toronto-Dominion Bank.

About DRI Healthcare Trust

The trust is managed by DRI Capital Inc., a pioneer in global pharmaceutical royalty monetization. Since its initial public offering in 2021, the trust has deployed more than $900-million (U.S.), acquiring more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga.